Who should attend?
Pharmaceutical multinationals, biotechnology and chemical companies with interest in Latin American and Central American countries
Benefits of attending:
- Recommended strategy in the region: key steps to optimize prosecution and accelerate grant with the least number of office actions possible
- From ANVISA in Brazil to new obstrusive Guidelines in Argentina and abusive Official Fees in Ecuador, are we seeing a negative trend or will this change in the coming years?
- Key developments and what to expect in 2015